Literature DB >> 7514907

The -158 (C-->T) promoter mutation is responsible for the increased transcription of the 3' gamma gene in the Atlanta type of hereditary persistence of fetal hemoglobin.

D G Efremov1, A J Dimovski, T H Huisman.   

Abstract

The Atlanta type of hereditary persistence of fetal hemoglobin (HPFH) is characterized by a mild elevation of Hb F (2% to 5% in heterozygotes), almost exclusively of the G gamma type (more than 90%). Gene-mapping analysis has identified this condition as a -G gamma-G gamma- arrangement with the -158 (C-->T) substitution in the promoters of both G gamma genes. We have reevaluated this condition in members of two families. Sequence analysis identified only two changes in the 3' gamma gene as compared with the A gamma gene from a chromosome with haplotype no. 3 (or Senegal), namely the -158 (C-->T) promoter mutation and the C-->G change in codon (CD) 136, which accounts for the -G gamma-G gamma- phenotype. The absence of any other nucleotide (nt) substitution provides genetic evidence that the -158 (C-->T) change is primarily responsible for the elevated Hb F levels associated with this condition. A quantitative reverse transcription/polymerase chain reaction (RT/PCR) procedure, presented in detail in this report, was developed to determine the effect of this mutation on the transcription of individual gamma genes in four individuals with the Atlanta type of HPFH. Both gamma-globin genes, ie, the (5') G gamma and the (3') G gamma-Atlanta genes of the Atlanta type of HPFH chromosome, expressed elevated amounts of transcripts, which were present in nearly equal amounts. This shows that the -158 (C-->T) mutation exerts its effect on the transcriptional rate of the gene with which it is associated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514907

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Hb Costa Rica or alpha 2 beta 2 77(EF1)His --> Arg: the first example of a somatic cell mutation in a globin gene.

Authors:  W E Rodriguez Romero; M Castillo; M A Chaves; G F Saenz; L H Gu; J B Wilson; E Baysal; N S Smetanina; J Y Leonova; T H Huisman
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

2.  Mechanism for fetal hemoglobin induction by histone deacetylase inhibitors involves gamma-globin activation by CREB1 and ATF-2.

Authors:  Jose Sangerman; Moo Seung Lee; Xiao Yao; Eugene Oteng; Cheng-Hui Hsiao; Wei Li; Sima Zein; Solomon F Ofori-Acquah; Betty S Pace
Journal:  Blood       Date:  2006-08-08       Impact factor: 22.113

3.  Intestinal transcription and synthesis of apolipoprotein AI is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene.

Authors:  S Naganawa; H N Ginsberg; R M Glickman; G S Ginsburg
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

4.  A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity.

Authors:  W S Yang; D N Nevin; R Peng; J D Brunzell; S S Deeb
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

5.  Absence of mutations in the promoter of the COL1A1 gene of type I collagen in patients with osteogenesis imperfecta type I.

Authors:  M C Willing; R L Slayton; S H Pitts; S P Deschenes
Journal:  J Med Genet       Date:  1995-09       Impact factor: 6.318

6.  Genetics in Macedonia-Following the international trends.

Authors:  Elena Sukarova-Angelovska; Aleksandar Petlichkovski
Journal:  Mol Genet Genomic Med       Date:  2018-02-20       Impact factor: 2.473

7.  The association of C3435T single-nucleotide polymorphism, Pgp-glycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy.

Authors:  Zoran Sterjev; Gordana Kiteva Trencevska; Emilija Cvetkovska; Igor Petrov; Igor Kuzmanovski; Jasmina T Ribarska; Aleksandra K Nestorovska; Nadica Matevska; Zorica Naumovska; Suzana Jolevska-Trajkovic; Aleksandar Dimovski; Ljubica Suturkova
Journal:  Neuropsychiatr Dis Treat       Date:  2012-04-19       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.